Omeros (NASDAQ:OMER) Earns Buy Rating from Analysts at Rodman & Renshaw

Rodman & Renshaw started coverage on shares of Omeros (NASDAQ:OMER) in a research note released on Thursday, Marketbeat Ratings reports. The firm issued a buy rating and a $9.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Omeros has a consensus rating of “Hold” and a consensus price target of $9.00.

Omeros Stock Down 2.9 %

Shares of Omeros stock opened at $6.75 on Thursday. Omeros has a 52-week low of $1.38 and a 52-week high of $7.51. The company has a 50 day moving average of $4.14 and a 200 day moving average of $4.11. The company has a market capitalization of $391.16 million, a P/E ratio of -2.92 and a beta of 1.47.

Institutional Trading of Omeros

Several institutional investors have recently modified their holdings of OMER. BNP Paribas Financial Markets lifted its position in shares of Omeros by 75.5% during the 1st quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 12,951 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in shares of Omeros during the 1st quarter worth approximately $85,000. Vanguard Group Inc. lifted its position in shares of Omeros by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock worth $11,213,000 after buying an additional 81,348 shares during the last quarter. Comerica Bank lifted its position in shares of Omeros by 20.0% during the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 5,000 shares during the last quarter. Finally, Cypress Capital Group increased its holdings in shares of Omeros by 40.0% in the 2nd quarter. Cypress Capital Group now owns 35,000 shares of the biopharmaceutical company’s stock valued at $142,000 after acquiring an additional 10,000 shares during the period. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.